Announcement

Collapse
No announcement yet.

STUDY: Placebo-controlled phase 3 study of oral BG-12 or glatiramer in MS

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • STUDY: Placebo-controlled phase 3 study of oral BG-12 or glatiramer in MS

    Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis

    Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT, CONFIRM Study Investigators; New England Journal of Medicine (NEJM) 367 (12), 1087-97 (Sep 2012)

    BACKGROUND
    BG-12 (dimethyl fumarate) is in development as an oral treatment for relapsing-remitting multiple sclerosis, which is commonly treated with parenteral agents (interferon or glatiramer acetate).

    METHODS
    In this phase 3, randomized study, we investigated the efficacy and safety of oral BG-12, at a dose of 240 mg two or three times daily, as compared with placebo in patients with relapsing-remitting multiple sclerosis. An active agent, glatiramer acetate, was also included as a reference comparator. The primary end point was the annualized relapse rate over a period of 2 years. The study was not designed to test the superiority or noninferiority of BG-12 versus glatiramer acetate.

    RESULTS
    At 2 years, the annualized relapse rate was significantly lower with twice-daily BG-12 (0.22), thrice-daily BG-12 (0.20), and glatiramer acetate (0.29) than with placebo (0.40) (relative reductions: twice-daily BG-12, 44%, P<0.001; thrice-daily BG-12, 51%, P<0.001; glatiramer acetate, 29%, P=0.01). Reductions in disability progression with twice-daily BG-12, thrice-daily BG-12, and glatiramer acetate versus placebo (21%, 24%, and 7%, respectively) were not significant. As compared with placebo, twice-daily BG-12, thrice-daily BG-12, and glatiramer acetate significantly reduced the numbers of new or enlarging T(2)-weighted hyperintense lesions (all P<0.001) and new T(1)-weighted hypointense lesions (P<0.001, P<0.001, and P=0.002, respectively). In post hoc comparisons of BG-12 versus glatiramer acetate, differences were not significant except for the annualized relapse rate (thrice-daily BG-12), new or enlarging T(2)-weighted hyperintense lesions (both BG-12 doses), and new T(1)-weighted hypointense lesions (thrice-daily BG-12) (nominal P<0.05 for each comparison). Adverse events occurring at a higher incidence with an active treatment than with placebo included flushing and gastrointestinal events (with BG-12) and injection-related events (with glatiramer acetate). There were no malignant neoplasms or opportunistic infections reported with BG-12. Lymphocyte counts decreased with BG-12.

    CONCLUSIONS
    In patients with relapsing-remitting multiple sclerosis, BG-12 (at both doses) and glatiramer acetate significantly reduced relapse rates and improved neuroradiologic outcomes relative to placebo. (Funded by Biogen Idec; CONFIRM ClinicalTrials.gov number, NCT00451451.).
    Dave Bexfield
    ActiveMSers

  • #2
    BG-12 has been slightly delayed. - Dave

    Biogen Idec Says FDA Extends MS Drug Review

    Biogen Idec Inc., the third-largest U.S. biotechnology company, said the Food and Drug Administration extended the review of its experimental multiple sclerosis medicine by three months.

    The FDA didn’t request more studies of the drug BG-12, the Weston, Massachusetts-based company said in a statement today. The three-month extension is a standard period, Biogen said.

    The drug is meant to treat relapsing-remitting MS, the most common form of the illness. The disease affects more than 2.1 million people worldwide and about 400,000 Americans, according to the National Multiple Sclerosis Society. Patients with RRMS get attacks that degrade their neurological function, followed by periods of recovery.
    Dave Bexfield
    ActiveMSers

    Comment

    Working...
    X